CD24 and Miyoshi myopathy: This work presents a rational approach to engineering BCMA-CD24-CAR-T cells that not only effectively target bulk MM tumor cells, but also substantially reduce the numbers of minimal residual MM cells and modulate the tumor microenvironment (Fig. 7).